PMN

Business Context and Reporting Period

Company: ProMIS Neurosciences Inc. (PMN)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: ProMIS is a clinical-stage biopharmaceutical company developing antibody therapies and therapeutic vaccines for neurodegenerative diseases, specifically targeting toxic misfolded proteins. The company utilizes a proprietary computational platform to identify disease-specific epitopes.
Key Pipeline:

• PMN310: Lead candidate for Alzheimer's Disease (AD); currently in Phase 1b (PRECISE-AD) clinical trial.
• PMN267: Candidate for Amyotrophic Lateral Sclerosis (ALS); preclinical stage.
• PMN442: Candidate for Multiple System Atrophy (MSA); preclinical stage.

Key Financial Metrics

Note: The 2024 Net Income was driven by a non-cash gain of $22.58 million from the change in fair value of warrant liabilities, offset by a $3.52 million loss on the issuance of securities in the July 2024 Private Placement.

Material Changes vs. Prior Period

• Financing Activity: In July 2024, the company completed a Private Investment in Public Equity (PIPE) offering raising approximately $30.3 million in gross proceeds. This significantly increased cash reserves compared to the prior year.
• Operating Expenses: Total operating expenses increased by $2.56 million (18%) to $16.83 million. Research and Development (R&D) expenses rose by $2.75 million (35%), primarily due to the advancement of the PMN310 Phase 1b clinical trial.
• Non-Operating Items: Other income increased by $18.56 million year-over-year, primarily attributable to a $22.6 million gain on the change in fair value of financial instruments (warrant liabilities) following shareholder approval of warrant terms in October 2024.
• Capital Structure: All outstanding Series 2 Convertible Preferred Shares were converted into Common Shares following the July 2024 financing.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Clinical Progress: The company initiated the Phase 1b PRECISE-AD trial for PMN310 in December 2024, aiming to enroll approximately 100 subjects. The focus is on safety, tolerability, and biomarker assessment.
• Liquidity: Management states that cash of $13.3 million as of December 31, 2024, is not sufficient to fund operations for at least 12 months from the issuance date. Additional financing is required to continue clinical activities.
• Going Concern: The company has incurred losses since inception and anticipates continued losses. The auditor has included an emphasis of matter paragraph regarding substantial doubt about the company's ability to continue as a going concern.

• Nasdaq Compliance: The company received notice in January 2025 of non-compliance with the Nasdaq minimum bid price requirement ($1.00). It has 180 days to regain compliance; failure may result in delisting.
• Internal Controls: Management identified a material weakness in internal control over financial reporting related to the review of fair value calculations for the July 2024 PIPE warrant liability.
• Development Risk: Product candidates are in early stages; there is no guarantee of regulatory approval or commercial success. The Alzheimer's disease field has historically seen high failure rates.
• Capital Needs: Failure to secure additional funding could force the company to delay, reduce, or terminate development programs.

Investor Verification Checklist

• Going Concern Status: Verify the timeline for the next financing round given the explicit statement that current cash is insufficient for 12 months of operations.
• Nasdaq Delisting Risk: Monitor the stock price to ensure it remains above $1.00 to avoid delisting proceedings, which could impact liquidity and investor confidence.
• Warrant Liability Accounting: Review the remediation plan for the material weakness in internal controls regarding fair value calculations, as this impacted the 2024 net income significantly.
• Clinical Trial Enrollment: Track the enrollment progress of the PRECISE-AD Phase 1b trial, as delays could increase burn rate and necessitate further capital raises.
• Dilution Potential: Assess the dilutive impact of outstanding warrants (over 57 million) and options, particularly the Tranche A and B warrants from the July 2024 PIPE which are subject to milestone events.